



Massachusetts Psychiatric Society's 34th Annual Psychopharmacology Update

Program Overview

Each year the psychopharmacology update course chair and cochair review feedback from the previous year including suggestions for topics of interest. Also, the chair has extensive experience consulting with psychiatrists who have psychopharmacology questions and become aware of prescribing issues that are not well understood by practitioners. From these sources a set of presentations was developed. The program begins with a discussion on the differential diagnosis and treatment of mania with psychosis, schizoaffective disorder, and schizophrenia. A second speaker will

focus on cannabis use in adults. After a break, a speaker will discuss hallucinogen persisting perception disorder. This will be followed by a speaker providing updates on ADHD treatments in adults. Following a lunch break, the program continues with a discussion on the treatment of agitation in patients with mania or schizophrenia. The final lecture will be on the topic of the treatment of substance use disorder during pregnancy and postpartum period. The program will end with questions and answers on any topic in psychopharmacology with a panel of the day's speakers.

Learning Objectives

At the conclusion of this activity, participants will be able to:

- Prescribe medications without being subject to undue influence by drug company marketing
- Select the most evidence-supported medications for efficacy and safety for patients with cannabis use
- Select the most evidence-supported medications for efficacy and safety for patients with hallucinogen persisting perception disorder
- Select the most evidence-supported medications for efficacy and safety for patients with ADHD
- Select the most evidence-supported medications for efficacy and safety for patients with agitation in context of mania or schizophrenia
- Select the most evidence-supported medications for efficacy and safety for patients with substance use disorder during pregnancy and postpartum period
- Select the most evidence-supported medications for efficacy and safety for patients with schizoaffective disorder

[CLICK TO REGISTER ONLINE](#)

AMA Credit Designation Statement

The Massachusetts Psychiatric Society designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Massachusetts Psychiatric Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.

Saturday
NOVEMBER 4, 2023
8:15 a.m.–4:00 p.m.

Virtual Program

Faculty

Bushra Awidi, MD

*Psychiatrist, Partial Hospital Program
Cape Cod & Islands CMHC*

*Child and Adolescent Psychiatrist
Massachusetts General Hospital*

Anderson Chen, MD

*Psychiatrist
Massachusetts General Hospital*

*Instructor in Psychiatry
Harvard Medical School*

Kevin P. Hill, MD, MHS

*Director, Division of Addiction Psychiatry
Beth Israel Deaconess Medical Center*

*Associate Professor of Psychiatry
Harvard Medical School*

Steven E. Locke, MD, DLFAPA

*Former Associate Professor of Psychiatry
Harvard Medical School*

*Affiliate Psychiatrist
Beth Israel Deaconess Medical Center*

*Principal
Behavioral Health Integration Solutions, LLC*

David N. Osser, MD

*Associate Professor of Psychiatry
Harvard Medical School
at VA Boston Healthcare System*

Edwin Raffi, MD, MPH

*Perinatal and Reproductive Psychiatrist
Massachusetts General Hospital's
Ammon-Pinizzotto Center for Women's
Mental Health*

*Director of Behavioral Health,
MGH HOPE clinic for Pregnant & Postpartum
Women with Substance Use Disorder*

*Instructor in Psychiatry
Harvard Medical School*

Sean Stetson, MD

*Assistant Professor of Psychiatry, BUSM;
secondary with HMS*

*Staff Psychiatrist / Director of Mental Health
Emergency Services, Boston VA*



Program Schedule

- 8:15-8:30 a.m.** **Welcome and Introduction**
Anderson Chen, MD, Activity Chair
David N. Osser, MD, Activity Co-Chair
- 8:30-9.30 a.m.** **Differential Diagnosis and Psychopharmacology Treatment of Mania with Psychosis, Schizoaffective Disorder, and Schizophrenia**
David N. Osser, MD
- 9:30-10:30 a.m.** **Cannabis Use in Adults**
Kevin P. Hill, MD, MHS
- 10:30-10.45 a.m.** **BREAK**
- 10:45-11:45 a.m.** **Hallucinogen Persisting Perception Disorder (HPPD): The Trip That Never Ends**
Steven Locke, MD, DLFAPA
- 11:45-12:45 p.m.** **ADHD Treatments in Adults**
Bushra Awidi, MD
- 12:45-1:30 p.m.** **LUNCH**
- 1:30-2.30 p.m.** **Treatment of Agitation in Patients with Mania or Schizophrenia**
Sean Stetson, MD
- 2:30-3:30 p.m.** **Treatment of Substance Use Disorder During Pregnancy and Postpartum Period**
Edwin Raffi, MD, MPH
- 3:30-4:00 p.m.** **More Questions and Answers**
Panel of the Speakers



34th Annual Psychopharmacology Update

REGISTRATION FEE

[] MPS/APA/MMS MEMBER	\$150
[] RESIDENT/FELLOW	\$15
[] NON-MEMBER	\$175
[] MEDICAL STUDENT	\$0

CLICK HERE TO [REGISTER](#). **Please note the link for the conference will be sent on November 3.** If you are unable to register online, please contact the office to register by phone.

Questions?

Call (781) 237-8100, 8 a.m.–4 p.m. Monday thru Friday